|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||92.20 - 95.05|
|52 Week Range||28.35 - 136.90|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Puma's (PBYI) shares jump in a year's time on its cancer drug Nerlynx's approval in the United States coupled with strategic collaborations.
Aradigm Corporation (NASDAQ:ARDM) and Puma Biotechnology, Inc. (NASDAQ:PBYI) both served up key updates in the biotechnology space this week, with each relating to a respective in-house development program. Here’s what happened with each company and what comes next for both. Aradigm Aradigm announced on Thursday that the FDA Antimicrobial Drugs Advisory Committee did not recommend […] The post Biotech Updates: Aradigm Corporation & Puma Biotechnology appeared first on Market Exclusive.
For Puma Biotechnology Inc’s (NASDAQ:PBYI) shareholders, and also potential investors in the stock, understanding how the stock’s risk and return characteristics can impact your portfolio is important. PBYI is exposedRead More...
Puma, Clovis and Incyte could outperform other midcap biotechs this year, an analyst says, listing the trio as his favorites for 2018.
Small-caps and large-caps are wildly popular among investors, however, mid-cap stocks, such as Puma Biotechnology Inc (NASDAQ:PBYI) with a market capitalization of $3.95B, rarely draw their attention from analysts andRead More...
Puma's (PBYI) shares skyrocket in the year so far on the approval of its cancer drug Nerlynx in the United States coupled with strategic collaborations.
How far off is Puma Biotechnology Inc (NASDAQ:PBYI) from its intrinsic value? Using the most recent financial data, I am going to take a look at whether the stock isRead More...
In this article, I’m going to take a look at Puma Biotechnology Inc’s (NASDAQ:PBYI) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject amongRead More...
Puma (PBYI) signs a licensing deal with Specialised Therapeutics Asia to commercialize its breast cancer drug Nerlynx in Australia, New Zealand and South East Asia.
Puma crashed after sales of its breast cancer drug crushed views but failed to live up to more bullish expectations.
Alan Auerbach took the helm as Puma Biotechnology Inc’s (NASDAQ:PBYI) CEO and grew market cap to USD$4.77B recently. Recognizing whether CEO incentives are aligned with shareholders is a crucial partRead More...
The Los Angeles-based company said it had a loss of $2.07 per share. Losses, adjusted for stock option expense, were $1.36 per share. The results exceeded Wall Street expectations. The average estimate ...
Shares of Puma Biotechnology Inc. fell more than 8% late Thursday after the biotech company reported an adjusted third-quarter loss in line with expectations, and sales that were above Wall Street forecasts. ...
Puma Biotechnology (PBYI) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
The pharma/biotech industry has witnessed strong Q3 results with many companies beating estimates for earnings and sales. Let's see if some small biotechs, due to report on Nov 9, follow suit.
Puma Biotechnology's (PBYI) only marketed product, Nerlynx (neratinib), for advanced breast cancer was launched in August. So Q3 is the first quarter in which Puma will record sales for Nerlynx.
Puma Biotechnology Inc. said it has secured a term loan of up to $100 million to market its drug Nerlynx, which was recently approved by the U.S. Food and Drug Administration as a treatment to reduce the risk of breast cancer recurrence. Los Angeles-based Puma (PBYI) said it has entered into a loan agreement with Silicon Valley Bank and Oxford Finance , a specialty finance firm that provides senior debt to life sciences and health-care services companies.
A former Puma Biotechnology Inc executive pleaded guilty on Thursday to U.S. charges that he traded on inside information ahead of announcements by the biopharmaceutical company about a drug it was developing to treat breast cancer. Robert Gadimian, the Los Angeles-based company's former senior director of regulatory affairs, pleaded guilty in federal court in Boston to seven counts of securities fraud over illicit trades that prosecutors say allowed him to earn over $1 million. "Mr. Gadimian has fully accepted responsibility for his conduct," his lawyer, Christopher Bruno, said.
Puma Biotechnology Inc (NASDAQ:PBYI), a biotechnology company based in United States, received a lot of attention from a substantial price increase on the NasdaqGS in the over the last fewRead More...